Page 648 - Read Online
P. 648

Page 12 of 12                             Adler et al. J Cancer Metastasis Treat 2019;5:45  I  http://dx.doi.org/10.20517/2394-4722.2019.03

                   testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline update. J Clin
                   Oncol 2013;31:3997-4013.
               28.  Harbeck N, Rody A. Lost in translation? Estrogen receptor status and endocrine responsiveness in breast cancer. J Clin Oncol
                   2012;30:686-9.
               29.  Crockard A, Bunger C, Harms J, Kawahara N, Mazel C, et al. Review of metastatic spine tumour classification and indications for surgery:
                   the consensus statement of the global spine tumour study group. Eur Spine J 2010;19:215-22.
               30.  Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level
                   meta-analysis of the randomised trials. Lancet 2015;386:1341-52.
               31.  Holtkamp W, Nagel GA, Wander HE, Rauschecker HF, von Heyden D. Hyperprolactinemia is an indicator of progressive disease and poor
                   prognosis in advanced breast cancer. Int J cancer 1984;34:323-8.
               32.  Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin
                   Oncol 2009;27:1160-7.
               33.  Sinn P, Aulmann S, Wirtz R, Schott S, Marmé F, et al. Multigene assays for classification, prognosis, and prediction in breast cancer: a
                   critical review on the background and clinical utility. Geburtshilfe Frauenheilkd 2013;73:932-40.
               34.  Chia SK, Speers CH, D'yachkova Y, Kang A, Malfair-Taylor S, et al. The impact of new chemotherapeutic and hormone agents on
                   survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007;110:973-9.
               35.  Wang M, Bünger CE, Li H, Wu C, Høy K, et al. Predictive value of Tokuhashi scoring systems in spinal metastases, focusing on various
                   primary tumor groups: evaluation of 448 patients in the Aarhus spinal metastases database. Spine (Phila Pa 1976) 2012;37:573-82.
               36.  Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, et al. Pertuzumab, Trastuzumab, and Docetaxel in HER2-positive metastatic breast
                   cancer. N Engl J Med 2015;372:724-34.
               37.  Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Comparisons between different polychemotherapy regimens for early breast cancer:
                   meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012;379:432-44.
               38.  Ulmer B, Richter M, Cakir B. The Tokuhashi score: significant predictive value for the life expectancy of patients with breast cancer with
                   spinal metastases. Spine (Phila Pa 1976) 2005;30:2222-6.
               39.  Balain B, Jaiswal A, Trivedi JM, Eisenstein SM, Kuiper JH, et al. The Oswestry risk index: an aid in the treatment of metastatic disease of
                   the spine. Bone Joint J 2013;95-B:210-6.
               40.  Tokuhashi Y, Matsuzaki H, Toriyama S, Kawano H, Ohsaka S. Scoring system for the preoperative evaluation of metastatic spine tumor
                   prognosis. Spine (Phila Pa 1976) 1990;15:1110-3.
               41.  Carlsson AM. Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale. Pain 1983;16:87-101.
               42.  Fisher CG, Ryken TC, Bilsky MH, Shaffrey CI, Berven SH, et al. A novel classification system for spinal instability in neoplastic disease:
                   an evidence-based approach and expert consensus from the spine oncology study group. Spine (Phila Pa 1976) 2010;35:E1221-9.
               43.  Harrington KD. Orthopedic surgical management of skeletal complications of malignancy. Cancer 1997;80:1614-27.
               44.  Taneichi H, Kaneda K, Takeda N, Abumi K, Satoh S. Risk factors and probability of vertebral body collapse in metastases of the thoracic
                   and lumbar spine. Spine (Phila Pa 1976) 1997;22:239-45.
               45.  Majeed H, Kumar S, Bommireddy R, Klezl Z, Calthorpe D. Accuracy of prognostic scores in decision making and predicting outcomes in
                   metastatic spine disease. Ann R Coll Sure Engl 2012;94:28-33.
               46.  Bullmann V, Liljenqvist UR. Operative treatment of spinal metastases. Orthopädie und Unfallchirurgie up2date 2010;5:279-94.
               47. Heyde CE, Gulow J, von der Höh N, Völker A, Jeszenszky D, et al. Results-adapted operative treatment options for spinal metastases.
                   Orthopäde 2013;42:734-45.
               48. Von Salis-Soglio G, Prietzel T. Diagnostic methods in suspected malignant bone and soft tissue tumors. Orthopade 2002;31:595-607.
               49.  Cho JH, Ha JK, Hwang CJ. Patterns of treatment for metastatic pathological fractures of the spine: the efficacy of each treatment modality.
                   Clin Orthop Surgn 2015;7:476-82.
               50.  Delank KS, Wendtner C, Eich HT, Eysel P. The treatment of spinal metastases. Dtsch Arztebl Int 2011;108:71-9.
               51.  Chen F, Xia YH, Cao WZ. Percutaneous kyphoplasty for the treatment of spinal metastases. Oncol Lett 2016;11:1799-806.
               52.  Josten C, Glasmacher S, Franck A. Indikationen und grenzen der minimal-invasiven stabilisierung der metastatisch befallenen wirbelsäule.
                   Orthopäde 2013;42:755-64. Available from: https://link.springer.com/article/10.1007%2Fs00132-013-2070-8. [Last accessed on 17 Apr
                   2019]
               53.  Toquart A, Graillon T, Mansouri N. Management of spinal metastasis by minimal invasive surgery technique: surgical principles,
                   indications: a literature review. Neurochirurgie 2016;62:157-64.
               54.  Utzschneider S, Weber P, Fottner, Wegener B, Jansson V, et al. Prognosis-adapted surgical management of bone metastases. Orthopäde
                   2009;38:308, 310-2, 314-5.
               55.  Chiras J, Baragan H, Jean B, Rose M. Interventional radiology in bone metastases. Bull Cancer 2007;94:161-9.
               56.  Nakatsuka A, Yamakado K, Takaki H, Uraki J, Makita M, et al. Percutaneous radiofrequency ablation of painful spinal tumors adjacent to
                   the spinal cord with real-time monitoring of spinal canal temperature: a prospective study. Cardiovasc Intervent Radiol 2009;32:70-5.
               57.  Zheng L, Chen Z, Sun M. A preliminary study of the safety and efficacy of radiofrequency ablation with percutaneous kyphoplasty for
                   thoracolumbar vertebral metastatic tumor treatment. Med Sci Monit 2014;20:556-63.
               58.  Delgado-López PD, Rodríguez-Salazar A, Martín-Velasco V, Castilla-Díez JM, Martín-Alonso J, et al. Total en bloc spondylectomy for
                   spinal tumours: technical aspects and surgical details. Neurocirugia 2017;28:51-66.
               59.  Gezercan Y, Çavuş G, Ökten AI. Single-stage posterolateral transpedicular approach with 360-degree stabilization and vertebrectomy in
                   primary and metastatic tumors of the spine. World Neurosurg 2016;95:214-21.
   643   644   645   646   647   648   649   650   651   652   653